

Approaches to treat disease are becoming increasingly complex and creative, with the biotech industry recently demonstrating its key role in the development of new drug modalities and technologies. To keep up with this relentless pace, companies rely more and more on external innovation and benefit greatly if they manage to also leverage innovation from within their organisation.



But how can companies 'organise' creativity and innovation? Is there a science behind developing new ideas? How to provide freedom to be creative, while supporting urgency and purpose at the same time?

We will dig into this topic with innovation experts and innovation makers in the field of biopharmaceutical and biotechnology.

## AGENDA

10:00	"The knowledge innovation matrix: In search of research and impact opportunities" - <b>Lykke Margot Ricard</b> , University of Southern Denmark	
	"From uncertainty to innovation: A matter of min <b>Kirstin Kohler</b> , Professor for user experience innovation at the University of Applied Sciences N	design and design
	"BioMed X Institute – Seeding biomedical innovat <b>Thomas Rückle</b> , BioMed X Institute in Heidelberg	ions" -
11:00	Active break, sponsored by "Die Techniker - TK"	
11:20	CELIS Challenges	
12:00	Speed Networking	
13:00	Wrap-up	REGISTRATION



SMART HUB



BID

PEOPLE






## **SPEAKERS**



Lykke Margot Ricard is Associate Professor of Innovation Management and Technology at the University of Southern Denmark (SDU) and Head of MSc Programme in Product Development and Innovation. She earned her PhD in Innovation and Technology Management from the Technical University of Denmark and holds a MSc from Copenhagen Business School. She publishes within the field of innovation management, public leadership and economic sociology in aligning societal challenges with public and private innovation efforts. Innovation systems and innovation in networks is a key feature of her expertise. She won the Christopher Pollitt Award by Sage Publishing for best published article in International Review of Public Administration in 2019.

29 June @10 am CEST







Thomas Rückle is the Head of Research at BioMed X Institute. In this role, he oversees all Research activities at the Institute and is the main liaison to the Pharma Partners.

Thomas studied Chemistry and Toxicology at the University of Ulm, Germany, where he received his PhD in Organic Chemistry in 1996. After two postdoctoral fellowships at the Federal Institute of Technology Lausanne (EPFL), Switzerland and at the Torrey Pines Institute for Molecular Studies, San Diego (CA), USA, he joined Serono International in Geneva (Switzerland). From 1998 to 2006 he led Research and Preclinical Programs in Autoimmune Diseases and Oncology. From 2007 onwards, Thomas held several global roles in Project Management and Translational Medicine of Neurodegenerative Diseases and Oncology. From 2012 to 2016 he was Director in Translational Medicine at Medicines for Malaria Venture, the world's leading NGO in antimalarial R&D. Prior to BioMed X Institute, he spent 3 years as Chief Development Officer at GeNeuro. Together with his teams, Thomas has brought over a dozen molecules from Research into clinical trials.

## REGISTRATION









